Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sparassis crispa polysaccharide extracts to preparing medicines for treating neurodegenerative diseases

A technology of neurodegeneration and polysaccharide extraction, which is applied in the field of medicine, can solve the problems of public use and loss of drugs with no obvious curative effect, and achieve obvious effects of neuroprotection, memory improvement and remarkable effect

Active Publication Date: 2015-10-07
北京中京丰创科技有限公司
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its etiology is still unclear, but its main pathological features are the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of intracytoplasmic inclusions called Lewy bodies, and there is no overtly available drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sparassis crispa polysaccharide extracts to preparing medicines for treating neurodegenerative diseases
  • Application of sparassis crispa polysaccharide extracts to preparing medicines for treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Preparation of Hydrangea Polysaccharide Extract

[0016] Hydrangea SC031 was passed through a fermenter to obtain a fermented liquid, centrifuged at 4000-5000 rpm for 5-10 minutes, the supernatant was discarded, and the precipitate was freeze-dried to obtain hydrangea toadstool powder, which was extracted with 100 times the amount of hot water at 80°C Twice, 3 hours each time, filter and recover the extract, concentrate to a relative density of 1.15-1.20 at room temperature, and vacuum dry to obtain the hydrangea polysaccharide extract.

Embodiment 2

[0018] Protective effect of hydrangea SC031 polysaccharide extract on differentiated PC12 cells damaged by neurotoxin 6-OHDA

[0019] In the present invention, the cell survival rate is used as an index, and the result detected by the MTT method reflects the degree of toxicity of hydrangea polysaccharide extract against neurotoxin 6-OHDA, so as to illustrate its neuroprotective effect.

[0020] Take the PC12 cells in the logarithmic growth phase, dilute them into a cell suspension of 3*105 cells / ml with complete medium, inoculate 100 μl per well in a 96-well plate, and culture them in a 37°C, 5% CO2 incubator for 24 hours. Remove the medium, add 100 μl hydrangea polysaccharide extract solution (final concentration 4 μg / ml, 8 μg / ml, prepared from the basic medium as a solvent), add 100 μl basic medium to the model group and control group, 4 in each group Repeat hole. After drug pretreatment for 3 hours, 6-OHDA (final concentration: 100 μmol / l) was added to the administration g...

Embodiment 3

[0024] The above example 1 Hydrangea SC031 polysaccharide extract sample repairs the abnormal function of mitochondria in PC12 cells caused by neurotoxin 6-OHDA

[0025] Molecular probe JC-1 can be used to measure mitochondrial membrane potential. JC-1 is a lipophilic cationic dye that selectively enters mitochondria. Can reversibly change from green to red when membrane potential is raised (Cossarizza et al. 1993). In healthy cells, the mitochondrial membrane potential is high, and JC-1 can spontaneously form complexes called J-aggregates with strong red fluorescence. On the other hand, in apoptotic or unhealthy cells with low mitochondrial membrane potential, JC-1 is still in a monomolecular configuration, and it can only show green fluorescence (Cossarizza et al. 1993).

[0026] Take the PC12 cells in the logarithmic growth phase, dilute them into a cell suspension of 3*105 cells / ml with complete medium, inoculate 1 ml per well in a 6-well plate, and culture them in a 37°...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of sparassis crispa polysaccharide extracts to preparing medicines for treating neurodegenerative diseases, and relates to the technical field of medicines. The sparassis crispa polysaccharide extracts are prepared through fermentation, ethanol extraction and vacuum drying; and in-vitro tests prove that the remarkable neuroprotection activity effect is achieved. The sparassis crispa polysaccharide extracts are simple in preparing method and low in cost, and can be used for preparing the medicines for treating the neurodegenerative diseases such as the Parkinson's disease and the senile dementia.

Description

technical field [0001] The invention discloses the use of hydrangea polysaccharide extract in preparing medicine for treating neurodegenerative diseases, and relates to the technical field of medicine. Background technique [0002] Parkinson's disease (PD) is a chronic degenerative disorder of the central nervous system. It can impair the patient's limb function, language ability, etc., clinically manifested as resting tremor, rigidity, bradykinesia and postural instability and cognitive and emotional impairment. Its etiology is still unclear, but its main pathological features are the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of intracytoplasmic inclusions called Lewy bodies, and the open use of drugs with no apparent effect. Contents of the invention [0003] The invention provides the use of hydrangea polysaccharide extract in the preparation of medicines for treating neurodegenerative diseases, which has obvious medical effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61P25/28C08B37/00
Inventor 王迪胡爽张峻榕曾浩权宇彤逯家辉闫国栋滕利荣
Owner 北京中京丰创科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com